Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05632809 | REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) | PHASE2 | RECRUITING | 39 | — | — | Jan 10, 2023 | Dec 31, 2027 | Mar 11, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| NKTR-255 combination (Durvalumab) | EXPERIMENTAL | Participants will receive vein over about 30 minutes. Participants receive the first dose within 72 hours (3 days) after you complete CRT and the second dose at 3 weeks after you complete CRT. Then, you will receive NKTR-255 one (1) time every 4 weeks after that for up to 1 year. Durvalumab Participants will receive durvalumab by vein over about 30 minutes. You will receive the first dose at 3 weeks after you complete CRT therapy. Then, you will receive durvalumab one (1) time every 4 weeks after that for up to 1 year |
| Name | Type | Description |
|---|---|---|
| NKTR-255 | DRUG | Given by IV (vein) |
| Durvalumab | DRUG | Given by IV (vein) |
Inclusion Criteria: 1. Age 18 years or older 2. Histologic diagnosis of non-small cell lung cancer 3. Written consent obtained before initiation of any study-related procedures 4. Definitive cancer treatment intent 5. Absence of concurrent malignancies at other sites, except low risk prostate cance...